Heather S FeigelsonHeather Spencer Feigelson, PhD, MPH

Heather Spencer Feigelson, PhD, MPH, is a cancer epidemiologist with expertise in genetic susceptibility and genomics. Much of her research focuses on genetic susceptibility to breast and prostate cancer, including genome-wide association. In addition, she has published several studies examining the influence of overweight and obesity on breast cancer. Her interests include cancer survivorship and lifestyle factors such as use of hormone therapy on risk of cancer. She is a member of the University of Colorado Cancer Center and active in the Cancer Research Network (CRN), a consortium of research organizations affiliated with nonprofit integrated healthcare delivery systems and the National Cancer Institute. She holds faculty appointments at both the University of Southern California and Emory University Rollins School of Public Health.

Institute for Health Research
10065 E. Harvard Ave Suite 300
Denver, CO 80231
heather.s.feigelson @ kp.org

Research

CURRENT


Statins & Lymphoid Malignancy Risk in a Large Multi-site Population-based Cohort
The goal of this study is to investigate whether statins, drugs widely used to lower cholesterol and prevent heart attack and stroke, may also benefit patients who are beingtreated for prostate cancer. We will analyze more than 5,000 patients' electronicmedical records from the Kaiser Permanente Northwest health care system and the Veterans Administration; these two systems have extensive electronic datathat will allow us to examine prostate cancer cases that were diagnosed after statin use became common. Our results could lead to clinical trials and the eventual development of effective and safe therapy that helps prevent and reduce prostate cancer recurrence after initial therapy. Because statins are already in use, new findings about their role in cancer could translate quickly into practice.
Role: Co-Investigator
Funder: National Cancer Institute

CESR Statins and Prostate Cancer
The goal of this study is to investigate whether statins, drugs widely used to lower cholesterol and prevent heart attack and stroke, may also benefit patients who are beingtreated for prostate cancer. We will analyze more than 5,000 patients' electronicmedical records from the Kaiser Permanente Northwest health care system and the Veterans Administration; these two systems have extensive electronic datathat will allow us to examine prostate cancer cases that were diagnosed after statin use became common. Our results could lead to clinical trials and the eventual development of effective and safe therapy that helps prevent and reduce prostate cancer recurrence after initial therapy. Because statins are already in use, new findings about their role in cancer could translate quickly into practice.
Role: Site Investigator
Funder: CESR

Treatment Patterns and Recurrence of DCIS across Multiple CESR Sites
The main goal of this project is to describe treatment patterns for DCIS over time, across KP regions, tumor characteristics, patient age and comorbidity status; estimate breast cancer recurrence and second breast cancer (both ipsilateral and contralateral) among women with DCIS by treatment type; describe the use of pre-operative MRI and sentinel lymph node biopsy (SLNB) over time, by region, tumor characteristics and patient age and determine whether SLNB or pre-operative MRI are associated with increased use of mastectomy.
Role: Principal Investigator
Funder: CESR

Lung Nodule
The goal of this study is to develop biomarkers that are useful in informing clinical management of CT detected lung nodules of indeterminate etiology. We will collect risk factor information along with a variety of biospecimens, including sputum, blood, and tissue specimens when available, from KPCO members with lung nodules. We hope to identify biomarkers measurable in non-invasively obtained specimens that can discriminate between benign and malignant lung nodules.
Role: Principal Investigator
Funder: University of Colorado Cancer Center

BRANCH II: Pilot
The Breast and Colon Health Study (BRanCH) phase II is a pilot study designed to test the feasibility of (1) collection urine and stool samples from women recently diagnosed with breast cancer, and (2) re-sample women who previously agreed to provide such samples.
Role: Principal Investigator
Funder: National Cancer Institute

COMPLETED


Characterizing genetic susceptibility to breast and prostate cancer: The BPC3
This project is part of the NIC cohort consortium that will pool resources from six large prospective studies to allow large scale investigation of genetic susceptibility to ER-negative breast cancers and advanced, aggressive prostate cancers.
Role: Co-Principal Investigator
Funder: National Cancer Institute/ National Institutes of Health

Improving Breast Cancer Surgery Quality through a Collaborative Surgery Database
The main goal of this project is to establish a multi-center electronic cancer surgery outcomes database with appropriate clinical elements, which will establish a mechanism for automated clinical data capture for evaluation of outcomes of cancer surgery using endpoints other than mortality.  Additionally, the resulting data registry will be used to evaluate comparative effectiveness for the following items:  to assess the impact of geographic location, patient demographic factors, and surgeon-specific variation in outcomes of initial breast cancer surgery. Role: Site Principal Investigator
Funder: National Cancer Institute

CRN Comparative Effectiveness Research in Genomic Personalized Medicine
The goal of this project is to establish infrastructure and conduct studies of comparative effectiveness for genetic tests related to colorectal cancer (CRC) risk and CRC treatment effectiveness.  This high priority topic could have a tremendous impact on improving health outcomes, reducing costs, influencing treatment decisions, and ultimately reducing the large CRC related disease burden.
Role: Site Principal Investigator
Funder: National Cancer Institute

Feasibility Study for Microbiome and Cancer
The goal of this study is develop recruitment tools and pilot test the recruitment of women to a cross-sectional study to determine how the bacteria in the colon are related to levels and types of estrogens in healthy women between the ages of 55 and 69 years.
Role: Principal Investigator
Funder: Kaiser Permanente Strategic Initiative Committee funds

Cancer Research Network Across Healthcare Systems: Pilot Study Does weight loss among postmenopausal women decrease risk of breast cancer? The major goal of this grant is to explore the feasibility of conducting a multi-site study of weight loss and postmenopausal breast cancer across the CRN.
Role: Principal Investigator
Funder: National Cancer Institute

Bowles EJ, Feigelson HS, Barney T, Broecker K, Sterrett A, Bischoff K, Engel J, Gundersen G, Sheehey-Jones J, Single R, Onitilo A, James TA, McCahill LE. Improving quality of breast cancer surgery through development of a national breast cancer surgical outcomes (BRCASO) research database. BMC Cancer 2012; Apr 3; 12(1): 136. PMID: 22472011

Feigelson HS, Goddard KAB, Johnson MA, Funk KC, Kulchak Rahm A, Kauffman TL, Chitale DA, Marchand LL, Richard CS. Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories. BMC Research Notes 2012; 5(1): 196 PMID: 22534075

Rahm AK, Feigelson HS, Wagner N, Le AQ, Halterman E, Cornish N, Dearing J.  Perception of Direct-To-Consumer Genetic Testing and Direct-To-Consumer Advertising of Genetic Tests among Members of a Large Managed Care Organization. Journal of Genetic Counseling 2012; 21(3):448-461 PMID: 22278218

Delate T, Bowles EJ, Pardee R, Wellman RD, Habel LA, Yood MU, Nekhlyudov L, Goddard KA, Davis RL, McCarty CA, Onitilo AA, Feigelson HS, Freml J, Wagner E. Validity of Eight Integrated Healthcare Delivery Organizations' Administrative Clinical Data to Capture Breast Cancer Chemotherapy Exposure. Cancer Epidemiology, Biomarkers, and Prevention 2012; 21(4): 673-680. PMID:22337532

McCahill LE, Single RM, Aiello Bowles EJ, Feigelson HS, James TA, Barney T, Engel JM, Onitilo AA. Variability in reexcision following breast conservation surgery. Journal of the American Medical Association 2012; 307(5): 467-475 PMID: 22298678

Haiman CA, Chen GK, Vachon CM et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nature Genetics 2011; 43(12): 1210-1214. PMID: 22037553

Lee P, Fu YP, Prokunina-Olsson L et al. Fine mapping of 14q24.1 breast cancer susceptibility locus. Human Genetics 2011; 131(3):479-490. PMID: 21959381

Schumacher FR, Berndt SI, Siddiq A et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Human Molecular Genetics 2011; 20(19): 3867-3875 PMID: 21743057

Berndt SI, Sampson J, Yeager M et al. Large-scale fine mapping of the HNF1B locus and prostate cancer risk. Human Molecular Genetics 2011; 20(16):3322-3329. PMID: 21576123

Chung CC, Ciampa J, Yeager M et al. Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. Human Molecular Genetics 2011; 20(14): 2869-2878. PMID: 21531787

Teras LR, Goodman M, Patel AV, Diver WR, Flanders WD, Feigelson HS. Weight loss and postmenopausal breast cancer in a prospective cohort of overweight and obese US women. Cancer Causes Control 2011; 22(4): 573-579. PMID: 21327461

Parikh H, Wang Z, Pettigrew KA et al. Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels. Human Genetics 2011; 129(6):675-685. PMID: 21318478

Beckmann L, Husing A, Setiawan VW et al. Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and prostate cancer cohort consortium (BPC3). Journal of Clinical Endocrinology & Metabolism 2011; 96(2): E360-E367. PMID: 21177793

Prokunina-Olsson L, Fu YP, Tang W et al. Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2. Cancer Epidemiology, Biomarkers, & Prevention 2010; 19(5): 1349-1355. PMID: 20406958

Hildebrand JS, Gapstur SM, Feigelson HS, Teras LR, Thun MJ, Patel AV. Postmenopausal hormone use and incident ovarian cancer: Associations differ by regimen. International Journal of Cancer 2010; 127(12): 2928-2935. PMID: 21351271

Small CM, Manatunga AK, Klein M et al. Menstrual cycle variability and the likelihood of achieving pregnancy. Reviews on Environmental Health 2010; 25(4): 369-378. PMID: 21268451

Patel AV, Bernstein L, Deka A et al. Leisure time spent sitting in relation to total mortality in a prospective cohort of US adults. American Journal of Epidemiology 2010; 172(4):419-429. PMID: 20650954

Canzian F, Cox DG, Setiawan VW et al. Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Human Molecular Genetics 2010; 19(19): 3873-3884. PMID: 20634197

Hildebrand JS, Gapstur SM, Feigelson HS, Teras LR, Thun MJ, Patel AV. Postmenopausal hormone use and incident ovarian cancer: Associations differ by regimen. International Journal of Cancer 2010; 127(12): 2928-2935. PMID: 21351271

Lindstrom S, Ma J, Altshuler D et al. A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Journal of Clinical Endocrinology & Metabolism 2010; 95(9):E121-E127. PMID: 20534771

Schumacher FR, Cheng I, Freedman ML et al. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Human Molecular Genetics 2010; 19(15): 3089-3101. PMID: 20484221

Wacholder S, Hartge P, Prentice R et al. Performance of common genetic variants in breast-cancer risk models. New England Journal of Medicine 2010; 362(11): 986-993. PMID: 20237344

Koutros S, Schumacher FR, Hayes RB et al. Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer. Cancer Research 2010; 70(6): 2389-2396. PMID: 20197460

Dossus L, Kaaks R, Canzian F et al. PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis 2010; 31(3):455-461. PMID: 19965896

Travis RC, Schumacher F, Hirschhorn JN et al. CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiology, Biomarkers, & Prevention 2009; 18(10):2734-2744. PMID: 19789370

Yeager M, Chatterjee N, Ciampa J et al. Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nature Genetics 2009; 41(10): 1055-1057. PMID: 19767755

Teras LR, Goodman M, Patel AV et al. No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk. Cancer Epidemiology, Biomarkers, & Prevention 2009; 18(9):2553-2557. PMID: 19723917

Canzian F, Kaaks R, Cox DG et al. Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). BMC Cancer 2009; 9:257. PMID: 19640273

Ahn J, Schumacher FR, Berndt SI et al. Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3). Human Molecular Genetics 2009; 18(19): 3749-3757. PMID: 19574343

Jacobs EJ, Rodriguez C, Newton CC et al. Family history of various cancers and pancreatic cancer mortality in a large cohort. Cancer Causes and Control 2009; 20(8): 1261-1269. PMID: 19396555

Lou H, Yeager M, Li H et al. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proceedings of the National Academy of Sciences U S A 2009; 106(19):7933-7938. PMID: 19383797

Thomas G, Jacobs KB, Kraft P et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nature Genetics 2009; 41(5):579-584. PMID: 19330030

Ahmed S, Thomas G, Ghoussaini M et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nature Genetics 2009; 41(5):585-590. PMID: 19330027

Calle EE, Feigelson HS, Hildebrand JS, Teras LR, Thun MJ, Rodriguez C. Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer 2009; 115(5):936-945. PMID: 19156895

McKay JD, McCullough ML, Ziegler RG et al. Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiology, Biomarkers, & Prevention 2009: 18(1):2 97-305. PMID: 19124512

Ahn J, Berndt SI, Wacholder S et al. Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nature Genetics 2008; 40(9):1032-1034. PMID: 19165914

Patel AV, Feigelson HS, Talbot JT et al. The role of body weight in the relationship between physical activity and endometrial cancer: results from a large cohort of US women. International Journal of Cancer 2008; 123(8):1877-1882. PMID: 18651569

Feigelson HS, Teras LR, Diver WR et al. Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II. Breast Cancer Research 2008; 10(4):R57. PMID: 18611262

Patel AV, Cheng I, Canzian F et al. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One 2008; 3(7):e2578. PMID: 18596909

Thomas G, Jacobs KB, Yeager M et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nature Genetics 2008; 40(3):310-315. PMID: 18264096

McCullough ML, Patel AV, Patel R et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiology, Biomarkers, & Prevention 2008; 17(1):73-79. PMID: 18187388

Cox DG, Bretsky P, Kraft P et al. Haplotypes of the estrogen receptor beta gene and breast cancer risk.  International Journal of Cancer 2008; 122(2):387-392. PMID: 17935138

Rodriguez C, Feigelson HS Deka A et al. Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort. Cancer Epidemiology, Biomarkers, & Prevention 2008; 17(3):655-660. PMID: 18349283

Setiawan VW, Schumacher FR, Haiman CA et al. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiology, Biomarkers, & Prevention 2007; 16(11):2237-2246 PMID: 18006912

Stevens VL, Patel AV, Feigelson HS, Rodriguez C, Thun MJ, Calle EE. Cryopreservation of whole blood samples collected in the field for a large epidemiologic study. Cancer Epidemiology, Biomarkers, & Prevention 2007; 16(10):2160-2163. PMID: 17932366

Chen YC, Kraft P, Bretsky P et al. Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiology, Biomarkers, & Prevention 2007; 16(10):1973-1981. PMID: 17932344

Stevens VL, McCullough ML, Pavluck AL et al. Association of polymorphisms in one-carbon metabolism genes and postmenopausal breast cancer incidence. Cancer Epidemiology, Biomarkers, & Prevention 2007; 16(6):1140-1147. PMID: 17548676

Hunter DJ, Kraft P, Jacobs KB et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nature Genetics 2007; 39(7):870-874. PMID: 17529973

Feigelson HS, Rodriguez C, Welch R et al. Successful genome-wide scan in paired blood and buccal samples. Cancer Epidemiology, Biomarkers, & Prevention 2007; 16(5):1023-1025. PMID: 17507632

Schumacher FR, Feigelson HS, Cox DG et al. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Research 2007; 67(7):2951-2956. PMID: 17409400

Yeager M, Orr N, Hayes RB et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nature Genetics 2007; 39(5):645-649. PMID: 17401363

Haiman CA, Dossus L, Setiawan VW et al. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Research 2007; 67(5):1893-1897. PMID: 17325027

McCullough ML, Stevens VL, Diver WR et al. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Research 2007; 9(1):R9. PMID: 17244366

Cox DG, Blanche H, Pearce CL et al. A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Breast Cancer Research 2006; 8(5):R54. PMID: 16987421

Feigelson HS, Patel AV, Diver WR, Stevens VL, Thun MJ, Calle EE. Transforming growth factor beta receptor type I and transforming growth factor beta1 polymorphisms are not associated with postmenopausal breast cancer. Cancer Epidemiology, Biomarkers, & Prevention 2006; 15(6):1236-1237. PMID: 16775189

Feigelson HS, Patel AV, Teras LR, Gansler T, Thun MJ, Calle EE. Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women. Cancer 2006; 107(1):12-21. PMID: 16718671

Jacobs EJ, Feigelson HS, Bain EB et al. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Research 2006; 8(2):R22. PMID: 16613616

Feigelson HS, Cox DG, Cann HM et al. Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. Cancer Research 2006; 66(4):2468-2475. PMID: 16489054

Patel AV, Calle EE, Pavluck AL, Feigelson HS, Thun MJ, Rodriguez C. A prospective study of XRCC1 (X-ray cross-complementing group 1) polymorphisms and breast cancer risk. Breast Cancer Research 2005; 7(6):R1168-R1173. PMID: 16457697

McCullough ML, Rodriguez C, Diver WR et al. Dairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiology, Biomarkers, & Prevention 2005; 14(12):2898-2904. PMID: 16365007

Small CM, Manatunga AK, Klein M et al. Menstrual cycle characteristics: associations with fertility and spontaneous abortion. Epidemiology 2006; 17(1):52-60. PMID: 16357595

Hunter DJ, Riboli E, Haiman CA et al. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nature Reviews Cancer 2005; 5(12):977-985. PMID: 16341085

Kraft P, Pharoah P, Chanock SJ et al. Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genetics 2005; 1(5):e68. PMID: 16311626

McCullough ML, Feigelson HS, Diver WR, Patel AV, Thun MJ, Calle EE. Risk factors for fatal breast cancer in African-American women and White women in a large US prospective cohort. American Journal of Epidemiology 2005; 162(8):734-742. PMID: 16120696

Small CM, Marcus M, Sherman SL, Sullivan AK, Manatunga AK, Feigelson HS. CYP17 genotype predicts serum hormone levels among pre-menopausal women. Human Reproduction 2005; 20(8):2162-2167. PMID: 15878919

Jacobs EJ, Thun MJ, Connell CJ et al. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiology, Biomarkers, & Prevention 2005; 14(1):261-264. PMID: 15668504

McKean-Cowdin R, Feigelson HS, Xia LY et al. BRCA1 variants in a family study of African-American and Latina women. Human Genetics 2005; 116(6):497-506. PMID: 15726418

Feigelson HS, Rodriguez C, Jacobs EJ, Diver WR, Thun MJ, Calle EE. No association between the progesterone receptor gene +331G/A polymorphism and breast cancer. Cancer Epidemiology, Biomarkers, & Prevention 2004; 13(6):1084-1085. PMID: 15184270

Feigelson HS, Jonas CR, Teras LR, Thun MJ, Calle EE. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiology, Biomarkers, & Prevention 2004; 13(2):220-224. PMID: 14973094

Feigelson HS, Jonas CR, Robertson AS, McCullough ML, Thun MJ, Calle EE. Alcohol, folate, methionine, and risk of incident breast cancer in the American Cancer Society Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiology, Biomarkers, & Prevention 2003; 12(2):161-164. PMID: 12582027

Pike MC, Kolonel LN, Henderson BE et al. Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. Cancer Epidemiology, Biomarkers, & Prevention 2002; 11(9):795-800. PMID: 12223421

Feigelson HS, McKean-Cowdin R, Henderson BE. Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 2002; 17(5):445-446. PMID: 12202634

Rodriguez C, Jacobs EJ, Patel AV et al. Jewish ethnicity and prostate cancer mortality in two large US cohorts. Cancer Causes and Control 2002; 13(3):271-277. PMID: 12020109

Calle EE, Rodriguez C, Jacobs EJ et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 2002; 94(9):2490-2501. PMID: 12015775

Calle EE, Rodriguez C, Jacobs EJ et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 2002; 94(2):500-511. PMID: 11900235

Feigelson HS, Calle EE, Robertson AS, Wingo PA, Thun MJ. Alcohol consumption increases the risk of fatal breast cancer (United States). Cancer Causes and Control 2001; 12(10):895-902. PMID: 11808708

Feigelson HS, Rodriguez C, Robertson AS et al. Determinants of DNA yield and quality from buccal cell samples collected with mouthwash. Cancer Epidemiology, Biomarkers, & Prevention 2001; 10(9):1005-1008. PMID: 11535555

McKean-Cowdin R, Feigelson HS, Pike MC, Coetzee GA, Kolonel LN, Henderson BE. Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. Cancer Research 2001; 61(3):848-849. PMID: 11221867

Feigelson HS, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Research 2001; 61(2):785-789. PMID: 11212283

McKean-Cowdin R, Feigelson HS, Ross RK, Pike MC, Henderson BE. Declining cancer rates in the 1990s. Journal of Clinical Oncology 2000; 18(11):2258-2268. PMID: 10829046

Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000; 21(3):427-433. PMID: 10688862

Feigelson HS, Henderson BE. Future possibilities in the prevention of breast cancer: role of genetic variation in breast cancer prevention. Breast Cancer Research 2000; 2(4):277-282. PMID: 11250721

Feigelson HS, McKean-Cowdin R, Pike MC et al. Cytochrome P450c17alpha gene (CYP17) polymorphism predicts use of hormone replacement therapy. Cancer Res 1999; 59(16):3908-3910. PMID: 10463580

Feigelson HS, Ross RK, Yu MC, Coetzee GA, Reichardt JK, Henderson BE. Sex steroid hormones and genetic susceptibility to breast and prostate cancer. Drug Metabolisms Review 1998; 30(2):421-434. PMID: 9606611

Conrad JK, Hollenbach KA, Fullerton JT, Feigelson HS. Use of prenatal services by Hispanic women in San Diego County. A comparison of urban and rural settings. Journal of Nurse Midwifery 1998; 43(2):90-96. PMID: 9581093

Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE. Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Research 1998; 58(4):585-587. PMID: 9485002

Feigelson HS, Henderson BE, Pike MC. Re: Recent trends in U.S. breast cancer incidence, survival, and mortality rates. Journal of the National Cancer Institute 1997; 89(23):1810-1812. PMID: 9392623

Crocitto LE, Feigelson HS, Yu MC, Kolonel LN, Henderson BE, Coetzee GA. A polymorphism in intron 6 of the CYP17 gene. Clinical Genetics 1997; 52(1):68-69. PMID: 9272718

Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Research 1997; 57(6):1063-1065. PMID: 9067272

Feigelson HS, Henderson BE. Estrogens and breast cancer. Carcinogenesis 1996; 17(11):2279-2284. PMID: 8968038

Feigelson BJ, Acosta JA, Feigelson HS, Findley A, Saunders EL. T1 breast carcinoma in women 70 years of age and older may not require axillary lymph node dissection. American Journal of Surgery 1996; 172(5):487-489. PMID: 8942550

Langer RD, Criqui MH, Feigelson HS, McCann TJ, Hamburger RN. IgE predicts future nonfatal myocardial infarction in men. Journal of Clinical Epidemiology 1996; 49(2):203-209. PMID: 8606321

Feigelson HS, Ross RK, Yu MC, Coetzee GA, Reichardt JK, Henderson BE. Genetic susceptibility to cancer from exogenous and endogenous exposures. Journal of Cellular Biochemistry Supplement 1996; 25:15-22. PMID: 9027593

Fronek A, Criqui MH, Feigelson HS. A simple screening method for peripheral arterial occlusive disease. Journal of Vascular Surgery 1995; 22(1):122. PMID: 7602705

Feigelson HS, Criqui MH, Fronek A, Langer RD, Molgaard CA. Screening for peripheral arterial disease: the sensitivity, specificity, and predictive value of noninvasive tests in a defined population. American Journal of Epidemiology 1994; 140(6):526-534. PMID: 8067346

Sprecher DL, Feigelson HS, Laskarzewski PM. The low HDL cholesterol/high triglyceride trait. Arteriosclerocis, Thrombosis, and Vascular Biology 1993; 13(4):495-504. PMID: 8466885

Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. New England Journal of Medicine 1992; 326(6):381-386. PMID: 1729621

Criqui MH, Langer RD, Fronek A, Feigelson HS. Coronary disease and stroke in patients with large-vessel peripheral arterial disease. Drugs 1991; 42 Suppl 5:16-21. PMID: 1726213